Moreover, as a low amount of STING in tumor cells was described as sufficient to partially trigger OV-mediated immunogenicity [27,28], we aim to implement future strategies to rescue its function in STING null tumors as preparatory to OV treatment. The gene discussed is STING1; the disease is neoplasm.